These are the classical measures. The former denotes the proportions of true cases of the disease which are actually detected, while the latter measures the ability of a test to identify correctly those who are disease free. Ideally any test combines high specificity and sensitivity, and so defines accurately those with and without the characteristic under consideration. In practice, however, sensitivity and specificity are 40- fold the chances remained low in absolute terms because oesophageal cancer per se is relatively uncommon. In the first study neither patient was fit for surgery, and in the second there was no difference in survival compared with that of an age and sex matched control population. A further factor inhibiting surveillance is that the natural history ofprogression from Barrett's epithelium to adenocarcinoma is not understood so that it is impossible to concentrate on patients at particular risk. Thus high grade dysplasia is common in patients who have developed cancer but is otherwise rare.9`' The case for screening is therefore faulty because the natural history of the disease is not understood, the early stage is inadequately recognised, and early treatment is not of clear benefit.
STOMACH
Endoscopic screening of asymptomatic patients is undertaken on a wide scale in Japan where benefits are believed to outweigh the costs and discomfort. In European populations where gastric cancer is less common endoscopic screening has been undertaken in patients with pernicious anaemia or after partial gastrectomy for benign ulcer disease where the risks of developing cancer are perceived to be raised.'2" Though the extent of risk is contested,'-'7 it seems likely that any material change only becomes evident some 20 years after gastric resection.' 516 Even then the rise in risk, of the order of a doubling, is small, and furthermore is likely to occur in a fairly elderly population where the benefits of curative surgery in terms of prolonging life are diminished and the risks of operative complications and postoperative death must be raised. In absolute terms the risk is still low -even after 30 years the risk is of the order of one case for every 300 patient years of follow up.
If prevalent screening studies indicate a high rate of appreciable abnormality then this may suggest that the latent asymptomatic phase may be prolonged, indicating that in an elderly population with a limited life expectancy the gain to the patient from surgery after detection of an asymptomatic lesion may be limited.
Most gastric cancers occur in patients without predisposing disease and therefore a better strategy might be to consider case finding in patients aged 40 24 and there is no inherent reason why the same should not be true in the colon. A greater problem may be sampling variability within the colon. Apart from interobserver variation in interpretation of biopsy specimens we have to take account of sampling variation. It seems plausible to suggest that the higher the proportion of dysplastic specimens the greater the chances of neoplastic change, but evidence is lacking.
If screening is effective it should improve prognosis. Controlled comparisons with unscreened patients are not available and the limited clinical data do not help. Published reports have typically described sets of six or seven cases2-30 and these have varied in Dukes's classification from almost all grade A to none of group A and mainly group C. Such an inconsistent pattern does not suggest that lesions have generally been detected early, and even if they were it would require prolonged follow up to take account of lead time bias before accepting improved outcome.
The costs of screening can be expected to be high. Collins and his colleagues estimated that given a perfect outcome, 50 cancers might be detected by a yearly colonoscopic surveillance programme requiring a total of nearly 10000 colonoscopies in 1000 patients. 22 Put another way, in 20 centres each with 50 patients at risk, a colonoscopist might expect at best to detect one cancer every fourth year while conducting 50 examinations a year.
It seems logical to recommend a screening rate which would be inversely proportional to the hazard. Unfortunately, it is difficult to derive a practical scheme. Thus in Chicago 99 patients with pancolitis were screened yearly with biopsy specimens being taken every 10 cm.3' Twenty six developed low or high grade dysplasia or cancer after 30 years from onset, half having low grade and a third high grade dysplasia.
Benefit has to be assumed; the authors do not present evidence on dysplasia progression rates nor do they give the number of true cancers or discuss their outcome. It has, for example, been suggested39 that Haemoccult slides be rehydrated before testing to overcome loss of sensitivity due to drying. Mandel and colleagues report a gain in sensitivity from 80-8% to 92-2% after the introduction of rehydration of Haemoccult slides in the University of Minnesota's colon cancer control study, with a fall in specificity from 97-7% to 90 4%. If we used the data of Hardcastle et al as an example we can examine the results of the apparently large gain in sensitivity while only modestly reducing specificity.4' In that study, in 27000 screened subjects 63 cancers were detected, or roughly 20 cancers detected for every 10000 screened. A gain of sensitivity of 12% will result in detecting two or three more tumours, but a loss of specificity of 7% will mean that 700 extra will need examination by colonoscopy. Such figures illustrate the care necessary in considering the beguiling case for surveillance and the relative technical merits of different procedures.
The virtues of screening programmes are not self evident; proof of benefit is generally lacking and indications of possible benefit are limited to colorectal cancer screening where improved test methods are needed.
